Edaravone for COVID-19: real-time analysis

Download Image

Post

c19early.org

Edaravone for COVID-19

1 study with 38 patients

Serious outcome risk

Edaravone

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Edaravone studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−50%

Mortality (1)−50%

RCTs (1)−50%

Late (1)−50%

00.511.5+

← Edaravone
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Jun 20 2022	Moslemi et al., Inflammopharmacology, doi:10.1007/s10787-022-01001-2	Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial
Jun 20 2022	75% lower ventilation (p=0.06) and 10% longer ICU admission (p=0.92). RCT 38 severe COVID-19 ICU patients showing lower need for endotracheal intubation, but no significant difference in mortality with edaravone.